GE HealthCare had received 510(k) clearance from the United States Food and Drug Administration (FDA) for MIM Contour ProtégéAI+ 2.0, an AI-enabled auto-contouring software to assist radiation oncology care teams with treatment planning. MIM Contour ProtégéAI+ 2.0 introduces new models, including a Magnetic Resonance (MR) Brain model, as well as an updated Computed Tomography (CT) Male Pelvis model, expanding clinical capabilities across key anatomical regions. The FDA clearance includes a Predetermined Change Control Plan (PCCP), which establishes a framework for introducing future model updates and enhancements.

This will help enable the expansion of models across additional anatomical regions and imaging modalities. Radiation therapy plays a central role in cancer care, used in nearly 60% of cases and for over 2 million U.S. patients annually. The radiation therapy field continues to evolve to meet increasingly complex patient needs, with emerging technologies helping clinicians deliver more precise, efficient care.

Manual contouring is one of the most time-intensive steps in radiation therapy planning. AI-based approaches can help make contouring more efficient while maintaining accuracy. The underlying AI models for MIM Contour ProtégéAI+ were developed and validated using multi-institution datasets and have demonstrated contour quality comparable to, or exceeding, traditional approaches, supporting consistent and reliable performance across clinical use cases.

Unlike traditional auto-contouring tools, MIM Contour ProtégéAI+ is designed to operate with minimal user interaction, initiating contouring automatically and helping enable automated processing of CT and MR images. Results can be exported directly into treatment planning systems or MIM Workflows, helping reduce manual contouring effort and providing care teams more time to focus on creating treatment plans for their patients. The software is part of the MIM portfolio within GE HealthCare?s radiation oncology ecosystem and is designed to integrate seamlessly into existing clinical workflows.

MIM Contour ProtégéAI+ 2.0 will be showcased at booth #202 during the American Association of Medical Dosimetrists 51st Annual Meeting taking place June 7-10, 2026 in Orlando, Florida.